Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Farup, PG; Hinterleitner, TA; Lukas, M; Hebuterne, X; Rachmilewitz, D; Campieri, M; Meier, R; Keller, R; Rathbone, B; Oddsson, E.
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
Inflamm Bowel Dis. 2001; 7(3):237-242
Doi: 10.1097%2F00054725-200108000-00009
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hinterleitner Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance. The goal of this trial was to compare the effects of mesalazine 4 g daily given as prolonged-release granules in packets of 1 g with that of prolonged-release tablets of 0.5 g. Two hundred twenty-seven patients with mild-to-moderate ulcerative colitis were randomized to treatment with two packets twice daily (Gr-b.i.d.), 1 packet four times daily (Gr-q.i.d.) or 2 tablets four times daily (Ta-q.i.d.) for 8 weeks. A disease activity index (ulcerative colitis disease activity index: UC-DAI) was calculated, and the granules were defined as noninferior to the tablets if the lower limit of the 95% CI for the differences was more than -1 UC-DAI score unit. Noninferiority of the granules compared with the tablets was demonstrated. The mean improvement in the UC-DAI in the treatment groups Gr-b.i.d., Gr-q.i.d., and Ta-q.i.d. were 3.2, 2.9, and 2.4, respectively; the proportion of complete responders in the three groups 39%, 37%, and 31%, respectively. There were no differences in side effects. Mesalazine 4 g daily given as prolonged-release granules twice and four times daily is at least as effective as prolonged-release tablets four times daily in patients with mild to moderate ulcerative colitis. The patients preferred the twice daily dosing.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Anti-Inflammatory Agents, Non-Steroidal - administration and dosage
- Colitis, Ulcerative - drug therapy
- Delayed-Action Preparations - administration and dosage
- Drug Administration Schedule - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Male - administration and dosage
- Mesalamine - administration and dosage
- Middle Aged - administration and dosage
- Severity of Illness Index - administration and dosage
- Treatment Outcome - administration and dosage
- Find related publications in this database (Keywords)
- clinical trial
- patient compliance
- drug therapy
- inflammatory bowel diseases
- mesalazine
- ulcerative colitis